MYD Stock Overview
A genetic testing and precision medicine company, develops genetic tests in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Myriad Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.30 |
| 52 Week High | US$25.80 |
| 52 Week Low | US$14.00 |
| Beta | 1.94 |
| 11 Month Change | -31.25% |
| 3 Month Change | -42.34% |
| 1 Year Change | -11.73% |
| 33 Year Change | -41.51% |
| 5 Year Change | -39.41% |
| Change since IPO | 492.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.4% | 0.8% | -0.4% |
| 1Y | -11.7% | -16.7% | 7.1% |
Return vs Industry: MYD exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: MYD underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| MYD volatility | |
|---|---|
| MYD Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MYD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MYD's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,700 | Paul Diaz | www.myriad.com |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer.
Myriad Genetics, Inc. Fundamentals Summary
| MYD fundamental statistics | |
|---|---|
| Market cap | €1.33b |
| Earnings (TTM) | -€110.66m |
| Revenue (TTM) | €785.71m |
1.7x
P/S Ratio-11.9x
P/E RatioIs MYD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYD income statement (TTM) | |
|---|---|
| Revenue | US$823.60m |
| Cost of Revenue | US$254.10m |
| Gross Profit | US$569.50m |
| Other Expenses | US$685.50m |
| Earnings | -US$116.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 69.15% |
| Net Profit Margin | -14.08% |
| Debt/Equity Ratio | 5.3% |
How did MYD perform over the long term?
See historical performance and comparison